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Abstract
BACKGROUND: Renal cell cancer (RCC) is a chemo-
resistant disease with no active chemotherapeutic agent
achieving objective response rates higher than 15%.
Clusterin is a cell survival gene that increases in human
renal tubular epithelial cells after various states of injury
and disease. Downregulation of clusterin, using anti-
sense oligonucleotides (ASO) , has recently been
shown to increase chemosensitivity in several prostate
cancer models. The objectives in this study were to
evaluate clusterin expression levels in human RCC and
normal kidney tissue, and to test whether clusterin ASO
could also enhance chemosensitivity in human RCC
Caki -2 cells both in vitro and in vivo. METHODS:
Immunohistochemical staining was used to character-
ize clusterin expression in 67 RCC and normal kidney
tissues obtained from radical nephrectomy specimens.
Northern blot analysis was used to assess changes in
clusterin mRNA expression after ASO and paclitaxel
treatment. The effects of combined clusterin ASO and
paclitaxel treatment on Caki-2 cell growth was exam-
ined using an MTT assay. Athymic mice bearing Caki-2
tumors were treated with clusterin ASO alone, clusterin
ASO plus paclitaxel, and mismatch control oligonucleo-
tides plus paclitaxel, over a period of 28 days with
measurement of tumor volumes once weekly over 8
weeks.RESULTS: Immunohistochemistry of normal and
malignant kidney tissue sections of 67 patients demon-
strated positive clusterin staining for almost all RCC
(98%) and an overexpression, compared to normal
tissue, in a majority of RCC (69%). Clusterin ASO, but
not mismatch control oligonucleotides, decreased clus-
terin mRNA expression in Caki -2 cells in a dose-
dependent and sequence-specific manner. Pretreat-
ment of Caki-2 cells with clusterin ASO significantly
enhanced chemosensitivity to paclitaxel in vitro. Char-
acteristic apoptotic DNA laddering was observed after
combined treatment with ASO plus paclitaxel, but not
with either agent alone. In vivo administration of
clusterin ASO plus paclitaxel acted synergistically to
increase apoptosis and significantly delay Caki-2 tumor
growth, compared to mismatch control oligonucleotide
plus paclitaxel. In addition, TUNEL staining revealed
increased apoptotic cells in tumors treated with cluster-
in ASO plus paclitaxel compared to treatment with either
clusterin ASO or paclitaxel alone. CONCLUSION: These
findings confirm that the use of clusterin ASO may be
a feasible strategy to enhance chemosensitivity for
patients with advanced RCC. Neoplasia (2001) 3,
360–367.
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Introduction
Renal cell cancers (RCCs) account for approximately 2% of
adult carcinomas with over 30,000 new cases per year in the
United States and an associated 12,000 deaths [1] .
Estimates of annual new diagnoses of RCC have been
increasing steadily [1,2 ] . Despite extensive evaluation of
many different treatment modalities, advanced metastatic
RCC remains highly resistant to systemic therapy. To date,
no chemotherapy is established for the treatment of
advanced kidney cancer with objective response rates higher
than 15% that justifies its use as a single agent [3 ] .
Combinations of chemotherapy plus hormonal agents have
been studied but likewise are ineffective and result in additive
toxicity. Nearly half of all patients with RCC die within 5 years
of diagnosis and 5-year survival for those with metastatic
disease is 5% to 10% [4] . Therefore, to make a significant
impact on survival, preclinical and clinical evaluation of new
agents and treatment programs to identify improved anti-
tumor activity are priorities in this refractory disease.
Advances in the field of nucleic acid chemistry offers one
attractive strategy to design antisense oligonucleotide
(ASO) -based therapeutic agents that specifically hybridize
with complementary mRNA regions of a target gene and
thereby inhibit gene expression by forming RNA/DNA
duplexes [5] . Several ASO targeted against specific genes
involved in neoplastic progression have been evaluated as
potential therapeutic agents [6–9] . Collectively, these
findings identify ASO as a novel class of antineoplastic
agents when designed for appropriate molecular targets.
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However, because numerous genes are involved in tumor
progression, inhibition of a single target gene will likely be
insufficient to inhibit tumor progression in a meaningful way.
In fact, combined use of ASO with other compounds, such as
chemotherapeutic agents, have been demonstrated to
produce more potent antineoplastic effects in several tumor
models [10–13] .
Clusterin, also known as testosterone-repressed pros-
tate message-2 (TRPM-2) or sulfated glycoprotein-2, was
first described in 1983 as a major secretory glycoprotein
produced by ram Sertoli cells [14] . It is associated with a
wide variety of physiologic and pathologic processes,
including tissue remodeling, lipid transport, membrane
protection, complement defense, and apoptotic cell death
[15] . Increased expression of clusterin is seen in a variety of
renal diseases such as renal dysplasia, membranous
glomerulonephritis, inherited polycystic renal diseases, and
RCC [16,17] . It is also induced following ureteric obstruc-
tion, ischemia/ reperfusion injury, and in nephrotoxic injuries
such as gentamicin nephrotoxicity and myoglobinuric failure
[18] . More recent observations suggest that clusterin acts in
a chaperone- like manner similar to that of small heat shock
proteins. It potently inhibits stress- induced protein precip-
itation in vitro and appears to be associated with cell survival
in vivo [19] . Inactivation of this gene could therefore impair
cellular repair mechanisms in response to external cell
death signals such as chemotherapy.
Paclitaxel is one of the most important anticancer drugs
developed in the past two decades and has shown
significant activity against a variety of adenocarcinomas
[20] . Polymeric micellar paclitaxel used in this study offers
a safe and convenient formulation for animal studies with
no significant toxicity [21] . We recently reported that
clusterin overexpression confers chemoresistance to pacli-
taxel in the human prostate LNCaP tumor model [22] . In
the present study, we demonstrate for the first time that
downregulation of a specific gene (clusterin) , using
sequence-specific ASO, enhances the response of human
RCC to paclitaxel chemotherapy both in vitro and in vivo.
Materials and Methods
Tumor Cell Line
Caki -2 is derived from a human clear cell carcinoma of
the kidney. It was purchased from the American Type
Culture Collection (Rockville, MD). Cells were maintained in
Mc Coy’s 5a medium (Life Technologies, Gaithersburg,
MD) supplemented with 10% heat- inactivated fetal calf
serum.
Chemotherapeutic Agents
Paclitaxel was purchased from Sigma (St. Louis, MO).
Stock solutions of paclitaxel were prepared with dimethyl
sulfoxide (DMSO), and diluted with PBS to the required
concentrations before each in vitro experiment. Polymeric
micellar paclitaxel used in these in vivo studies was
generously supplied by Dr. Helen M. Burt (Faculty of
Pharmaceutical Sciences, University of British Columbia,
Vancouver, Canada) .
Antisense Clusterin Oligonucleotides (Clusterin ASO)
Phosphorothioate oligonucleotides used in this study
were purchased from La Jolla Pharmaceuticals (La Jolla,
CA) . The sequence of clusterin ASO corresponding to the
human clusterin translation initiation site was 50 -CAGCAG-
CAGAGTCTTCATCAT-30. A two-base clusterin mismatch
oligonucleotide (50 -CAGCAGCAGAGTATTTATCAT-30 )
was used as control.
Treatment of Cells with Oligonucleotides
Lipofectin, a cationic lipid (Life Technologies) was used
to increase oligonucleotide uptake of cells. Caki -2 cells were
treated with various oligonucleotide concentrations after
preincubation for 20 minutes with 20 g/ml lipofectin in
serum free OPTI-MEM (Life Technologies) . Four hours
after the beginning of the incubation, the medium containing
oligonucleotides and lipofectin was replaced with standard
culture medium described above.
Northern Blot Analysis
Total RNA was isolated from cultured Caki -2 cells and
Caki -2 tumor tissues using the acid–guanidium thiocya-
nate–phenol–chloroform method. Electrophoresis, hybrid-
ization, and washing conditions were carried out as
previously reported [9] . Human clusterin and GAPDH
cDNA probes were generated by reverse transcription–
PCR from total RNA of human kidney using primers 50 -
AAGGAAATTCAAAATGCTGTCAA-30 (sense) and 50 -
ACAGACAAGATCTCCCGGCACTT-30 (antisense) for
clusterin, and 50-TGCTTTTAACTCTGGTAAAGT-30 (sense)
and 50 -ATATTTGGCAGGTTTTTCTGA-30 (antisense) for
GAPDH. Density of bands for clusterin was normalized
against that of GAPDH by densitometric analysis.
MTT Assay
The in vitro growth inhibitory effects of clusterin ASO
plus paclitaxel on Caki -2 cells were assessed using the
MTT assay as described previously [23] . Briefly, 1104
cells were seeded in each well of 96-well microtiter plates
and allowed to attach overnight. Cells were then treated
once daily with 500 nM ASO for 2 days. Following ASO
treatment, cells were treated with various concentrations of
paclitaxel. After 48 hours of incubation, 20 l of 5 mg/ml
MTT (Sigma) in PBS was added to each well, followed by
incubation for 4 hours at 378C. The formazan crystals were
dissolved in DMSO. The optical density was determined
with a microculture plate reader (Becton Dickinson
Labware, Lincoln Park, NJ) at 540 nm. Absorbance values
were normalized to the values obtained for the vehicle-
treated cells to determine the percentage of survival. Each
assay was performed in triplicate.
DNA Fragmentation Analysis
The nucleosomal DNA degradation was analyzed as
described previously with a minor modification [23] . Briefly,
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1105 Caki -2 cells were seeded in 10-cm culture dishes
and allowed to adhere overnight. After treatment with ASO
plus paclitaxel using the same schedule as described above,
cells were harvested and then lysed in a solution containing
100 mM NaCl, 10 mM Tris pH 7.4, 25 mM EDTA and 0.5%
SDS. After centrifugation, supernatants were incubated with
300 g/ml proteinase K for 5 hours at 658C and extracted
with phenol–chloroform. The aqueous layer was treated with
0.1 volume of 3 M sodium acetate, and the DNA was
precipitated with 2.5 volumes of 95% ethanol. Following
treatment with 100 g/ml RNAse A for 1 hour at 378C, the
sample was electrophoresed on a 2% agarose gel and
stained with ethidium bromide.
Immunohistochemical Staining
Sections from formaldehyde- fixed, paraffin -embedded
tissue from radical nephrectomy specimens for RCC were
deparaffinized by passing slides through 5-minute washes
of xylene (2 ) , 100% EtOH, 95% EtOH, and 70% EtOH,
successively. Endogenous peroxidase was blocked with 3%
hydrogen peroxide in absolute methanol. Slides were
autoclaved for 15 minutes in DAKO target retrieval solution
(Dako, Carpinteria, CA) , and blocked with 1% bovine serum
albumin for 1 hour at room temperature. After an overnight
incubation at 48C with 1:50 antihuman clusterin goat
polyclonal IgG (Santa Cruz Biotechnology, Santa Cruz,
CA) , sections were covered with 1:200 HRP-conjugated
antigoat IgG (Santa Cruz Biotechnology) . Peroxidase
activity on sections was detected by immersion in freshly
mixed 3-30 diaminobenzidine tetrachloride (0.6 mg/ml)
(Sigma) and 0.003% hydrogen peroxide for 5 minutes.
The sections were then counterstained with hematoxylin,
dehydrated and cleared, and placed under a coverslip. Each
specimen was read independently by a pathologist (M. A.)
and a urologist (T. Z. ) . Clusterin -staining intensity was
scored from 0 (no staining at all ) , +1 (weak) , +2
(medium), +3 (strong) to +4 (very strong staining) and the
percentage of stained tissue per section was assessed. For
each patient (n=67) , normal kidney tissue was compared
with corresponding RCC tissue.
Assessment of In Vivo Tumor Growth
Approximately 1106 of Caki -2 cells were inoculated
subcutaneously with 0.1 ml of Matrigel (Becton Dickinson
Labware, Bedford, MA) in the flank region of 6- to 8-week-
old male athymic mice (BALB/c strain; Harlan Sprague–
Dawley, Indianapolis, IN) under halothane anesthesia (5%
induction and 1.5% maintenance concentration) . When
Caki -2 tumors grew to 1 cm in diameter, usually 8 to 10
weeks after injection, mice were randomly selected for
treatment with clusterin ASO alone, clusterin ASO plus
paclitaxel, or mismatch control oligonucleotides plus pacli-
taxel. Each experimental group consisted of eight mice. After
randomization, 12.5 mg/kg clusterin ASO or mismatch
control oligonucleotide was injected intraperitoneally once
daily into each mouse for 28 days. From day 10 to 14, and
from day 24 to 28, 0.5 mg polymeric micellar paclitaxel was
administered once daily by intravenous injection. Tumor
volume was measured once weekly and calculated by the
formula lengthwidthdepth0.5236 [24] . Data points
were reported as mean tumor volumes±standard deviation.
All animal procedures were performed according to the
guidelines of the Canadian Council on Animal Care and with
appropriate institutional certification.
TUNEL Staining
A modified TUNEL technique [25] was used to detect
apoptotic cells in Caki -2 tumors using the ApopTag in situ
apoptosis detection system (Oncor, Gaithersburg, MD).
Briefly, sections from formaldehyde- fixed, paraffin-embed-
ded Caki -2 tumors were deparaffinized and endogenous
peroxidase was blocked as described above for immunohis-
Figure 1. Enhanced expression of clusterin in human RCC. Expression of clusterin in benign ( left ) and malignant ( right ) human kidney tissue ( renal cell
carcinoma, clear cell type, Fuhrmann grade III – IV ) . Deparaffinized tissue sections were labeled with antihuman clusterin goat polyclonal antibodies using the
immunoperoxidase technique. RCC shows strong clusterin staining ( dark reaction product ) , whereas no clusterin expression can be seen in normal kidney tissue.
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tochemical staining. After pretreatment with proteinase K (10
g/ml) , slides were labeled with biotinylated poly dU,
introduced by terminal deoxy- transferase, and then stained
using antidigoxigenin-peroxidase according to manufac-
ture’s protocol. Peroxidase activity on sections was detected
by immersion in freshly mixed 3-30 diaminobenzidine
tetrachloride (0.6 mg/ml) (Sigma) and 0.003% hydrogen
peroxide for 5 minutes. The sections were then counter-
stained with hematoxylin, dehydrated and cleared, and
placed under a coverslip. The number of positively stained
cells /high power field (hpf ) in five random fields was
counted and averaged.
Statistical Analysis
The in vitro cytotoxic effects of antisense or mismatch
oligonucleotide and paclitaxel were analyzed with the use of
a repeated-measure analysis of variance (ANOVA) model.
Synergy between clusterin ASO and paclitaxel was analyzed
by calculation of the fractional product parameter according
to the fractional product method as previously described
[26] . The other data were analyzed by Student’s t test. The
levels of statistical significance were set at P <.05 ( two-
sided) , and all statistical calculations were done by use of
the Statview 5.0 software (Abacus Concepts, Berkeley,
CA) .
Results
Enhanced Expression of Clusterin in Human RCC
Clusterin immunostaining was performed in normal
kidney and RCC tissue of 67 patients. Histologic classifica-
tion of RCC revealed clear cell patterns in 56 cases (84.5%),
the rest of sections showing either granular cell (6%) or
papillary cell patterns (9%). Staining of cytoplasmic
clusterin was heterogenous both in normal and malignant
tissues. Positive clusterin staining was found in almost all
RCC (97%) and clusterin overexpression, compared to
normal tissue, was observed in a majority (69%) of RCC.
Fifty- three percent of normal kidney tissue samples (distant
from RCC) showed no or only weak staining for clusterin,
compared to only 15% of RCC (Figure 1, Table 1) .
Table 1. Results of Clusterin Immunostaining in Normal Kidney and RCC
Paraffin -Embedded Tissue Sections from 67 Patients.
Normal tissue RCC tissue
Intensity of clusterin immunostaining*
0 11 (16%) 2 (3%)
+1 25 (37%) 8 (12%)
+2 25 (37%) 33 (49%)
+3 6 (16%) 15 (22%)
+4 0 (0%) 9 (13%)
Percentage of clusterin - stained tissue
0–25% 33 (49%) 14 (21%)
25–50% 19 (28%) 18 (27%)
50–75% 13 (19%) 20 (30%)
75–100% 2 (3%) 15 (22%)
*Intensity and positivity of clusterin immunostaining were assessed by an
immunoscore (0 to +4 ) comparing normal and malignant tissue in each
patient.
Figure 2. Sequence -specific and dose -dependent inhibition of clusterin
expression by clusterin ASO in Caki - 2 cells. Caki - 2 cells were treated daily
with various concentrations of clusterin ASO or a two -base clusterin mismatch
oligonucleotide as a control for 2 days, total RNA was extracted from culture
cells, clusterin and GAPDH mRNA levels were analyzed by Northern blotting.
No Tx indicates untreated cells ( control ) . Clusterin mRNA levels were
quantified ( after normalization to GAPDH mRNA levels ) by laser densitom-
etry. Each column represents the mean value of triplicate analysis with
standard deviation. Numbers on the Y axis symbolize arbitrary densitometric
units. ** and *, differ from control (P< .01 and P< .05, respectively ) by
Student’s t test.
Figure 3. Effect of paclitaxel treatment on clusterin expression of Caki - 2 cells
in vitro. Cells were treated with various concentrations of paclitaxel for 48
hours, mRNA was then extracted and analyzed for clusterin levels by Northern
blotting. Clusterin mRNA levels increased in a dose -dependent manner by
paclitaxel treatment at concentrations up to 100 nM. Quantitative analysis of
clusterin mRNA levels ( after normalization to GAPDH mRNA levels ) was
performed by laser densitometry. Each column represents the mean value of
triplicate analysis with standard deviation. Numbers on the Y axis symbolize
arbitrary densitometric units.
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Sequence-Specific and Dose-Dependent Inhibition of
Clusterin Expression by Clusterin ASO in Caki -2 Cells
Northern blot analysis was used to determine the effect
of treatment with clusterin ASO on clusterin mRNA
expression in Caki -2 cells. As shown in Figure 2, daily
treatment of Caki -2 cells with clusterin ASO (50, 100,
500, or 1000 nM) for 2 days reduced clusterin mRNA
levels by 42%, 58%, 61%, and 64%, respectively, whereas
clusterin mRNA expression was not affected by mismatch
control oligonucleotides at any of the employed concen-
trations.
Effects of Paclitaxel Treatment on Clusterin mRNA Expres-
sion in Caki -2 Cells and Tumors
Northern blot analysis was used to determine the effects
of paclitaxel treatment on clusterin mRNA expression in
Caki -2 cells in vitro and tumors in vivo, respectively. As
shown in Figure 3, clusterin mRNA induction increased in a
dose-dependent manner after paclitaxel treatment in vitro up
to 73% at concentrations of 100 nM.
To determine whether paclitaxel changes clusterin
mRNA expression in Caki -2 tumors in vivo, 0.5 mg
polymeric micellar paclitaxel was administered intrave-
nously once daily over 10 days with harvest of tumors for
mRNA extraction 1 day later. In nude mice bearing Caki -2
tumors, clusterin mRNA levels increased by 15% after
treatment with paclitaxel compared to untreated control
(Figure 4 ) .
Downregulation of Clusterin Expression by Clusterin ASO in
Caki -2 Tumors
To determine whether ASO treatment inhibits clusterin
expression in Caki -2 tumors in vivo, tumor-bearing nude
mice were given 12.5 mg/kg clusterin ASO or mismatch
control oligonucleotides intraperitoneally once daily over 28
days with tumors harvested for mRNA extraction 1 day
later. Treatment with clusterin ASO resulted in a 51%
reduction in clusterin mRNA levels in Caki -2 tumors
Figure 4. Effects of single and combined treatment with either clusterin ASO,
mismatch control oligonucleotide or micellar paclitaxel on clusterin expression
of Caki - 2 tumors in vivo. For that purpose, six athymic mice bearing Caki - 2
tumors were randomly selected as control ( no treatment ) ( Lane 1 ) ,
treatment with either clusterin ASO (Lane 2 ) , mismatch control oligonucleo-
tide ( Lane 3 ) , or micellar paclitaxel alone (Lane 4 ) , clusterin ASO plus
micellar paclitaxel ( Lane 5 ) or mismatch control oligonucleotides plus
micellar paclitaxel ( Lane 6 ) . After randomization, 12.5 mg / kg clusterin
ASO or mismatch control oligonucleotides were injected intraperitoneally once
daily for 28 days. From day 10 to 14, and from day 24 to 28, 0.5 mg polymeric
micellar paclitaxel was administered once daily by intravenous injection.
Tumors of all mice were harvested on day 29 for mRNA extraction. Compared
to control, clusterin ASO treatment decreased clusterin mRNA levels by 51%,
whereas paclitaxel increased clusterin mRNA levels by 15%. Combined
treatment with clusterin ASO and paclitaxel decreased clusterin mRNA levels
by 28%. Quantitative analysis of clusterin mRNA levels (after normalization to
GAPDH mRNA levels ) was performed by laser densitometry. Each column
represents the mean value of triplicate analysis with standard deviation.
Figure 5. Effect of combined treatment with clusterin ASO and paclitaxel on
Caki - 2 cell growth and apoptosis. (A ) Caki - 2 cells were treated daily with
either 500 nM clusterin ASO or mismatch control oligonucleotides once daily
for 2 days. Following oligonucleotide treatment, the medium was replaced with
medium containing various concentrations of paclitaxel. After 48 hours of
incubation, cell viability was determined by the MTT assay. Each data point
represents the mean of triplicate analysis with standard deviation. Clusterin
ASO treatment significantly enhanced chemosensitivity of paclitaxel in a
dose -dependent manner ( two - sided, P= .022, ANOVA ) , reducing the IC50
( i.e., the concentration that reduces cell viability by 50%) of paclitaxel by 80%
(320 nM to 65 nM) , whereas mismatch control oligonucleotides had no effect.
The combined effects between clusterin ASO and paclitaxel were synergistic
(P< .05 ) , as determined by an analysis that utilized the fractional product
method [26 ] . (B ) DNA fragmentation assay was performed to compare
induction of apoptosis after combined treatment with 500 nM clusterin ASO
and paclitaxel ( 7.5 nM ) . After the same treatment schedule described above,
characteristic DNA laddering was observed only after combined treatment
with clusterin ASO and paclitaxel.
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compared to mismatch control oligonucleotide- treated
tumors (Figure 4 ) .
Enhanced Chemosensitivity of Caki -2 Cells In Vitro After
Clusterin ASO Treatment
To determine whether treatment with clusterin ASO
enhances the cytotoxic effects of paclitaxel, Caki -2 cells
were treated with 500 nM clusterin ASO or mismatch control
oligonucleotides once daily for 2 days and then incubated
with medium containing various concentrations of paclitaxel
for 2 days. The MTT assay was then performed to determine
cell viability. As shown in Figure 5A, clusterin ASO treatment
significantly enhanced chemosensitivity of paclitaxel in a
dose-dependent manner ( two-sided, P=.022, ANOVA),
reducing the IC50 ( i.e., the concentration that reduces cell
viability by 50%) of paclitaxel by 80% (320 nM to 65 nM),
whereas mismatch control oligonucleotides had no effect.
The combined effects between clusterin ASO and paclitaxel
were synergistic (P<.05) , as determined by an analysis that
utilized the fractional product method [26] .
DNA fragmentation assay was performed to compare
induction of apoptosis after combined treatment with 500 nM
clusterin ASO and 10 nM paclitaxel. After the same
treatment schedule described above, characteristic apop-
totic DNA laddering was observed only after combined
treatment with clusterin ASO and paclitaxel (Figure 5B ) .
Figure 6. Effect of combined treatment with clusterin ASO plus micellar paclitaxel in Caki - 2 tumor growth. (A ) Mice bearing Caki - 2 tumors were randomly selected
for treatment with clusterin ASO plus micellar paclitaxel, mismatch control oligonucleotides plus micellar paclitaxel or clusterin ASO alone. When Caki - 2 tumors
became approximately 1 cm in diameter, 12.5 mg / kg clusterin ASO or mismatch control oligonucleotide was injected intraperitoneally for 28 days. From day 10 to
day 14 and from day 24 to 28, 0.5 mg micellar paclitaxel was daily administered by intravenous injection. Tumor volume was measured once weekly and calculated
by the formula, lengthwidthdepth0.5236. Each point represents the mean tumor volume in each experimental group containing eight mice with standard
deviation. *Differ from control (P< .05 ) by two - sided Student’s t test. (B ) , (C ) , and (D ) After completion of the same treatment schedule described (A ) , Caki - 2
tumors were harvested from each treatment group for detection of apoptosis using TUNEL staining. Sections of paraffin -embedded Caki - 2 tumors were stained with
digoxigenin - dUTP antibody to identify apoptotic cells. (B ) Caki - 2 tumor after treatment with clusterin ASO andmicellar paclitaxel (mean number of apoptotic cells /
high power field: 11.6 ) . (C ) Caki - 2 tumor after treatment with mismatch control oligonucleotides and micellar paclitaxel (mean number of apoptotic cells / high
power field: 4.1 ) . (D ) Caki - 2 tumor after treatment with clusterin ASO alone (mean number of apoptotic cells / high power field: 2.3 ) .
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Enhanced Chemosensitivity of Caki -2 Tumors In Vivo After
Clusterin ASO Treatment
Male athymic mice bearing Caki -2 tumors approximately
1 cm in diameter were randomly selected for treatment with
clusterin ASO plus paclitaxel, mismatch control oligonucleo-
tides plus paclitaxel, or clusterin ASO alone. Mean tumor
volume was similar at the beginning of treatment in each of
these groups (365 to 375 mm3) . After randomization, 12.5
mg/kg clusterin ASO or mismatch control oligonucleotides
were injected intraperitoneally once daily for 28 days. From
day 10 to 14, and from day 24 to 28, 0.5 mg polymeric
micellar paclitaxel was administered once daily by intra-
venous injection. As shown in Figure 6A, clusterin ASO
enhanced micellar paclitaxel chemosensitivity in Caki -2
tumors, causing a 50% reduction in mean tumor volume 7
weeks after initiation of treatment, compared to treatment
with mismatch control oligonucleotides and paclitaxel ( two-
sided, P<.05) . In vivo, the combined effects between
clusterin ASO and paclitaxel were also synergistic
(P<.05) , as analyzed by the fractional product method
[26] . In addition, TUNEL staining detected a three- fold
increase in the numbers of apoptotic cells in Caki -2 tumors
treated with clusterin ASO plus micellar paclitaxel (mean
number of apoptotic cells /high power field: 11.6) , compared
to those treated with mismatch control oligonucleotides plus
micellar paclitaxel (mean number of apoptotic cells /high
power field: 4.1) , or clusterin ASO alone (mean number of
apoptotic cells /high power field: 2.3) (Figure 6B  D ) .
Under the experimental conditions used in the above in
vivo experiments, no side effects associated with ASO
treatment and/or chemotherapy were observed (except one
animal developing ascites, 3 weeks after clusterin ASO
treatment was finished) .
Discussion
Numerous systemic therapies have been studied to assess
their activity in advanced, metastatic RCC. From 1990
through October 1998, 33 chemotherapeutic agents were
studied in 51 phase II trials comprising 1347 patients [4 ] . No
chemotherapeutic agent produced response rates that would
justify its use as a single-agent therapy. Hormonal therapy
with medroxyprogesterone produces infrequent responses
( <10%) and had no effect on survival [27] . Only a few
patients exhibit complete or partial responses to immuno-
logic agents like interferon and/or interleukin-2 but most do
not respond, and there are few long- term survivors
[1,28,29] . Despite extensive evaluation of many different
treatment modalities, advanced RCC remains highly resist-
ant to systemic therapy. Therefore, novel therapeutic
strategies targeting molecular mechanisms mediating che-
moresistance are required.
Recent preclinical studies have provided proof of principle
evidence that targeting antiapoptotic genes using ASO
enhances apoptosis induced by conventional cytotoxic
chemotherapy [10–12] . Clusterin is one of many antiapop-
totic genes involved in cancer progression and the develop-
ment of chemoresistance. Acting in a chaperone- like
manner similar to small heat shock proteins, it helps prevent
apoptosis induced by external stimuli such as chemother-
apeutic agents [19] . We recently demonstrated for several
prostate cancer models that the efficacy of chemotherapeu-
tic agents can be improved by combination with clusterin
ASO [21,30] . In the kidney, increased expression of
clusterin is observed in a number of acute and chronic
states of renal injury and disease. However, little is known
about changes of clusterin expression levels in kidney
cancer. Based on the analysis of only four patients, Parczyk
et al. [17 ] reported a three- fold overexpression of clusterin
in human RCC compared to normal kidney tissue. In our
study, we compared normal and malignant kidney tissues of
67 patients using clusterin immunostaining. Positive clusterin
staining ( +1 to +4) was observed in almost all RCC (97%)
and increased clusterin expression compared to normal
tissue in a majority of RCC (69%). Fifty- three percent of
normal kidney tissue samples distant from RCC showed no
or only weak staining for clusterin (0 to +1) consistent with
findings of other investigators [17,31] . To clarify the func-
tional role of increased clusterin expression in RCC, we then
tested the effects of clusterin ASO on human Caki -2 RCC
cell growth and whether clusterin ASO could enhance the
cytotoxic effects of paclitaxel in this model system.
Phosphorothioate clusterin ASO used in this study
significantly inhibited expression of clusterin mRNA in
Caki -2 cells both in vitro and in vivo. Sequence specificity
was confirmed using a two-base clusterin mismatch
oligonucleotide, which had no effects on clusterin expression
in Caki -2 cells. When used alone, antisense or mismatch
oligonucleotide treatment had no effect on Caki -2 cell
growth. However, when administered in combination with
other cell death stimuli, like cytotoxic chemotherapy,
clusterin ASO enhanced Caki -2 cell apoptosis both in vitro
and in vivo. Pretreatment of Caki -2 cells with clusterin ASO
reduced the IC50 of paclitaxel by 80%, thereby enhancing
apoptosis induced by these agents. Consistent with these in
vitro results, synergistic effects of combined use of clusterin
ASO plus paclitaxel was also observed in vivo. Systemic
administration of clusterin ASO plus polymeric micellar
paclitaxel suppressed the Caki -2 tumor growth by 50%,
compared to treatment with mismatch control oligonucleo-
tides plus paclitaxel. Detection of increased apoptotic cells
after combined ASO and chemotherapy by TUNEL staining
in Caki -2 tumors suggest that decrease in tumor progression
rates after combined clusterin ASO plus paclitaxel resulted
from enhanced chemotherapy- induced apoptosis rather
than decreased cell proliferation.
The results in the present study suggest that increased
clusterin helps mediate RCC progression by inhibiting
apoptotic cell death induced by several kinds of therapies,
including cytotoxic chemotherapy. Decreasing clusterin-
mediated chemoresistance by clusterin ASO may provide a
feasible and safe strategy to enhance chemosensitivity in
advanced RCC. The preclinical data presented here provide
proof of principle support for designing clinical studies
employing combined clusterin ASO plus paclitaxel therapy
for patients with advanced RCC.
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